Schema-Root.org logo

 

  cross-referenced news and research resources about

 GlaxoSmithKline

Schema-Root.org logo
images:  google   yahoo YouTube
spacer

updated Sat. March 9, 2019

-
GlaxoSmithKline plc (NYSE:GSK)'s price-to-sales ratio of 2.34 is creating a long-term opportunity in the value in its stock. The broad GlaxoSmithKline plc industry has an average P/S ratio of 4.78, which is significantly better than the sector's 7.6. In the past 13-year record, this ratio went down as low as 1.94 ...
GlaxoSmithKline (LON:GSK)'s stock had its “hold” rating reiterated by investment analysts at Deutsche Bank in a report issued on Friday, March 23rd, MarketBeat.com reports. They presently have a GBX 1,440 ($20.62) target price on the stock. Deutsche Bank's price target would suggest a potential upside ...

The US broker Jefferies has tweaked its price targets for AstraZeneca PLC (LON:AZN) and GlaxoSmithKline PLC (LON:GSK) ahead of first-quarter results, while maintaining its positive stance on the stocks of both businesses. AZ's valuation moves to £56 a share, around £6 higher than the current share ...
GlaxoSmithKline plc (LSE:GSK) is considered a high growth stock. However its last closing price of £14.296 left investors wondering whether this growth has already been factored into the share price. Below I will be talking through a basic metric which will help answer this question. Check out our latest ...
PetMed Express (NASDAQ:PETS): Cramer likes the stock but he prefers Idexx Labs (NASDAQ:IDXX) and Zoetis (NYSE:ZTS) more. Novartis AG (NYSE:NVS): It's a good stock. However, Cramer prefers GlaxoSmithKline (NYSE:GSK) as the stock yields 6% and CEO Emma Walmsley is turning the industry ...
British pharmaceutical major GlaxoSmithKline is putting Horlicks up for sale. The health food drink brand sold widely in India and also consumed in parts of Asia and the UK is up for a “strategic review,” the company said in a statement on March 27. The move is triggered by GSK's need to fund a $13 billion ...

The British pharma giant GlaxoSmithKline has had a consumer health joint venture with Switzerland's Novartis for the last few years. However, GSK has just struck a $13 billion deal with its partner to take control of the whole thing. The joint venture sells products such as Nicotinell nicotine patches, Panadol ...
GlaxoSmithKline logo GlaxoSmithKline (NYSE:GSK) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday, February 21st. According to Zacks, “Glaxo beat estimates for both earnings and sales in Q4. Performance of new products has been ...
nd so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Once again, our agenda is modest. We hope to catch up on our reading, escort Mrs. Pharmalot to a highbrow cultural establishment and take ...
If we could take a snapshot right now, there would be three major arguments for buying GlaxoSmithKline stock. First, the company's dividend yields 6.88%. That's the highest yield among big pharma companies and one of the highest yields in healthcare. Although Glaxo hasn't increased its dividend in a ...
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn't want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? One way to find these companies is by ...
As a severe flu season continues to unfold in the U.S., GlaxoSmithKline is touting phase 3 study data showing its Fluarix Tetra can protect young children who ... In children six to 35 months of age, Glaxo's vaccine was 63.2% effective against moderate-to-severe flu, and 49.8% effective against any flu, the ...
GlaxoSmithKline logo Brandes Investment Partners LP lifted its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 6.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,262,946 shares of the pharmaceutical company's ...
GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals Intl (NYSE:VRX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ...
2/27/2018 – GlaxoSmithKline had its “buy” rating reaffirmed by analysts at HSBC Holdings plc. They now have a GBX 1,925 ($26.60) price target on the stock. 2/26/2018 – GlaxoSmithKline was given a new GBX 1,475 ($20.38) price target on by analysts at Jefferies Group LLC. They now have a “buy” rating ...
GlaxoSmithKline has seen precious few takers for its $730,000 gene therapy for a rare and life-threatening immune illness known as “bubble-boy disease.” Now a tiny startup thinks it can succeed where the British giant is struggling. In almost two years since Glaxo's Strimvelis came to the market, just five ...
“This study is a valuable addition to our understanding of how to manage patients with biologic therapies,” study investigator Ken Champan said in a statement. Glaxo, though, has more to worry about in terms of competition than just Xolair. While Teva's Cinqair has been in the mix since March, 2016, the ...

GlaxoSmithKline PLC (GSK.LN) said on Monday that its majority-owned ViiV Healthcare joint venture has reported positive interim results from a study of dolutegravir, a treatment for adults with both HIV and tuberculosis. GSK said the ViiV phase IIIb study of dolutegravir showed the treatment was effective ...
GlaxoSmithKline plc (NYSE:GSK) delivered an ROE of 62.17% over the past 12 months, which is an impressive feat relative to its industry average of 10.75% during the same period. However, whether this above-industry ROE is actually impressive depends on if it can be maintained. Sustainability can be ...
For example, analysts who follow Glaxo have been raising their earnings projections going forward and with good reason. Bears zone in too much on future Advair competition (which has been kept at bay for the most part) but ignore what Glaxo has coming down the track. Furthermore the viability of the ...
Endo, GlaxoSmithKline close to settling testosterone liability cases ... Endo and GlaxoSmithKline have entered into a memorandum of understanding regarding a potential testosterone settlement. (Image: Pixabay) ... They're joined as defendants in some cases by former marketing partner GlaxoSmithKline.
GlaxoSmithKline said it will also receive a seat on the board of the gene-therapy company. The deal comes after a review by the British pharmaceutical major of its rare-disease unit. Glaxo cited as part of the rationale for the deal its decision to focus on respiratory and HIV/infectious-disease programs as ...
GlaxoSmithKline (GSK) is a British multinational pharmaceutical company with headquarters in Brentford, Middlesex. The company classifies its business portfolio into three business segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. Because it's a British multinational company, GSK ...
With analysts forecasting GlaxoSmithKline plc (LSE:GSK) to report triple digit earnings growth in the coming 12 months, it's important to take a step back and think through this promising sentiment. Those invested in the stock should contemplate the factors that are causing this projected increase, as the ...
GlaxoSmithKline CEO Emma Walmsley signaled this week that the company is going to fight for every scrap on the commercial table while pushing a turnaround on the pipeline. And she just picked up an unearned score after a major threat to their Advair franchise ran into a serious delay. The big stumble ...
When I started to investigate GlaxoSmithKline's (GSK) then future triple combo for COPD, I would never have thought it could be such a controversial story. And even now, that the long-awaited Trelegy Ellipta is finally on the shelves, there is no clarity. Today we finally learnt how much it sold in its first few ...
GlaxoSmithKline plcGSK reported core earnings of 72 cents per American depositary share in the fourth quarter of 2017, surpassing the Zacks Consensus Estimate of 69 cents. The bottom line was up 11% at constant exchange rate (CER) compared with the year-ago figure. Glaxo's shares have lost 9.4% ...
GlaxoSmithKline notifies SEC, DOJ of new questions in China bribery probe. by Eric Palmer |. Feb 7, 2018 10:51am. GlaxoSmithKline has yet to fully extricate itself from a bribery scandal that surfaced in 2013. U.K. authorities are still investigating. ... GlaxoSmithKline's China bribery imbroglio is the scandal that just won't die.
GlaxoSmithKline PLC (GSK.LN) said that it was ... Glaxo said that it had taken a tax charge of GBP1.6 billion on its 2017 earnings due to the recently passed U.S. tax reform, but expects it to lower its effective tax rate on adjusted profits in 2018 by two to three percentage points. The company declared a 23 ...
Good day ladies and gentlemen and welcome to the GSK 2017 Full Year Results call. During the presentation, your lines will remain on listen-only. If you require assistance at any time, please key star, zero on your telephone and a coordinator will be happy to assist you. I'd like to advise all parties this ...
GlaxoSmithKline said on Wednesday its earnings could slip this year, after a better-than-expected performance in the fourth quarter, as the drugmaker faces increased competition in its core respiratory and HIV businesses. After growing adjusted earnings per share (EPS) 4 percent in 2017, at constant ...
GlaxoSmithKline plc (NYSE:GSK) – Stock analysts at Jefferies Group lifted their FY2017 earnings per share (EPS) estimates for shares of GlaxoSmithKline in a research report issued to clients and investors on Tuesday, according to Zacks Investment Research. Jefferies Group analyst J. Holford now ...
GlaxoSmithKline plc (NYSE:GSK)'s interesting series of developments are underway around the US stock market these days. Now trading with a market value of 90.56B, the company has a mix of catalysts and obstacles that spring from the nature of its operations. In light of the many issues surrounding this ...
In 3Q17, GlaxoSmithKline (GSK) reported revenues close to 1.7 billion pounds from vaccines sales, a year-over-year (or YoY) increase of 5% on a reported basis. The company witnessed sales worth 816 million pounds for its vaccines franchise in the US market in 3Q17, a YoY increase of 13% on a ...
In 3Q17, GlaxoSmithKline (GSK) reported revenues close to 1.1 billion pounds from the sale of its human immunodeficiency virus (or HIV) products, which is year-over-year (or YoY) growth of 16% on a reported basis and 13% on a constant exchange rate (or CER). The company witnessed sales worth 681 ...
With an ROE of 64.55%, GlaxoSmithKline plc (LSE:GSK) outpaced its own industry which delivered a less exciting 9.57% over the past year. But what is more interesting is whether GSK can sustain this above-average ratio. Sustainability can be gauged by a company's financial leverage – the more debt it ...
New product launches will play a pivotal role in reinforcing GlaxoSmithKline's leadership in respiratory segment. Dolutegravir franchise is expected to continue to dominate the HIV segment in 2018. Vaccines will continue to be a high-growth market for GlaxoSmithKline all the way till year 2020. GSK'916 ...
GlaxoSmithKline's Emma Walmsley has grabbed headlines with some of the top management changes she's made since taking over as CEO last March, namely poaching Luke Miels from rival AstraZeneca to head up pharmaceuticals and appointing Roche and Calico veteran Hal Barron as chief scientific ...
In a stark intervention over the extra costs being incurred, Phil Thomson, president of global affairs at GlaxoSmithKline (GSK), made clear that something approaching the figure would have to be spent whatever the outcome of trade talks. In evidence to the Commons health select committee, he said he ...
Their view was heard but repeatedly ignored and with Witty's successor Emma Walmsley billing herself as a 'continuity candidate', Woodford felt “the prospect of a Glaxo breakup now looks more remote than ever.” However, I believe that if the group continues as a conglomerate, it could still deliver decent ...
While they don't always decide in favor of pharma's hot new launches or pricey cancer drugs, the influential cost watchdogs at England's NICE have given their final nod to GlaxoSmithKline's "bubble boy syndrome" therapy at a price of £594,000 ($714,000). It's good news for Glaxo, which won European ...
It also nabs McVeigh, who was most recently GlaxoSmithKline's VP of worldwide business development transactions and investment management. At the British Big Pharma, he also managed its portfolio of R&D equity investments in biotech partners, as well as early-stage venture capital funds, putting him ...
GlaxoSmithKline (NYSE:GSK) is a stock that is attracting interest because of the generous dividend yield it pays out. The company presently pays out an attractive 5.91% yield which is almost double the industry average and treble the yield of the S&P500. Moreover Glaxo has a sales multiple of 2.1 which is ...
GlaxoSmithKline said it is cutting an undisclosed number of jobs at its Irvine plant in North Ayrshire, Scotland. Employees were told last week. According to the Herald, 55 positions will be eliminated; however, 11 new jobs that will be created under a new organization will offset the overall loss of headcount.
DIVIDENDS: Dividends could be on the chopping block as Glaxo's new chief executive, Emma Walmsley, decides where to invest the company's increasingly tight cash flow, says Hargreaves Lansdown. Sales of the pharmaceutical's blockbuster product Advair/Seretide, a combination inhaler, are declining.
With regard to Glaxo potentially buying Pfizer's consumer healthcare business, I think the chances of this happening are now slim to none. Although Walmsley expressed interest in augmenting the company's already formidable consumer healthcare unit by picking up Pfizer's portfolio last July, she did so ...
The U.K.'s National Institute for Health and Care Excellence issued final draft guidance 1 approving the GlaxoSmithKline (GSK 2) gene therapy, Strimvelis, for an ultra-rare immune deficiency condition known as bubble boy syndrome. At nearly $717,000, the list price for the one-time treatment makes ...
GlaxoSmithKline plc logo Shore Capital reissued their hold rating on shares of GlaxoSmithKline (LON:GSK) in a research report released on Wednesday, November 22nd, MarketBeat reports. GSK has been the topic of a number of other research reports. Liberum Capital reiterated a buy rating and issued a ...
GlaxoSmithKline plc logo HSBC reissued their buy rating on shares of GlaxoSmithKline (LON:GSK) in a research report sent to investors on Wednesday, November 22nd. They currently have a GBX 1,925 ($25.91) price objective on the stock. GSK has been the subject of several other reports. J P Morgan ...
THE new battlefront in the $30 billion a year global toothpaste war is Australia's Federal Court, where GlaxoSmithKline has accused Colgate of using dodgy tests in Nepal to trick people with iffy ivories into buying its ... Glaxo spent $95 million last year on “marketing and selling”, its financials show.


 

news and opinion


 


 


 


 


schema-root.org

     glaxosmithkline
       brands

pharmaceutical industry:
     allergan
     ariad
     astrazeneca
     baxter
     eli lilly
     glaxosmithkline
     merck
     mylan
     novartis
     pfizer
     products
     purdue pharma
     research
     takeda
     teva
     upjohn
     valeant